CATRIDECACOG

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

US Approved Rx (2013)

First approved in 2013

Approval Year

Substance Class	Protein Created by `admin` on `Mon Mar 31 20:56:15 GMT 2025` Edited by `admin` on `Mon Mar 31 20:56:15 GMT 2025`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	NU23Q531G1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CATRIDECACOG

Official Name

English

CATRIDECACOG (GENETICAL RECOMBINATION)

Preferred Name

English

HUMAN RECOMBINANT FACTOR XIII SUBUNIT A DIMER

Common Name

English

COAGULATION FACTOR XIII A SUBUNIT (RECOMBINANT)

Common Name

English

COAGULATION FACTOR XIII A-SUBUNIT RECOMBINANT

Common Name

English

RECOMBINANT COAGULATION FACTOR XIII A-SUBUNIT

Common Name

English

TRETTEN

Brand Name

English

CATRIDECACOG [JAN]

Common Name

English

HUMAN FACTOR XIII (A2) HOMODIMER (ALLELE F13A*1B), RECOMBINANT DNA ORIGIN

Common Name

English

BLOOD-COAGULATION FACTOR XIII (SYNTHETIC HUMAN A-CHAIN PRECURSOR), DIMER

Common Name

English

Catridecacog [WHO-DD]

Common Name

English

RECOMBINANT COAGULATION FACTOR XIII

Common Name

English

COAGULATION FACTOR XIII RECOMBINANT HUMAN

Common Name

English

catridecacog [INN]

Common Name

English

NOVOTHIRTEEN

Brand Name

English

Classification Tree Code System Code

WHO-VATC

QB02BD11

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

WHO-ATC

B02BD11

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

FDA ORPHAN DRUG

174803

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

EMA ASSESSMENT REPORTS

NOVOTHIRTEEN (AUTHORIZED:CONGENITAL FACTOR XIII A-SUBUNIT DEFICIENCY)

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

FDA ORPHAN DRUG

73993

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

FDA ORPHAN DRUG

168603

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

Code System Code Type Description

WIKIPEDIA

Catridecacog

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

CAS

606138-08-3

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

ChEMBL

CHEMBL2108282

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

FDA UNII

NU23Q531G1

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

RXCUI

1488293

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

SMS_ID

100000124525

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

JAPANESE REVIEW

NOVOTHIRTEEN

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

APPROVED MARCH 2015

DAILYMED

NU23Q531G1

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

NCI_THESAURUS

C174766

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

INN

8817

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

EVMPD

SUB32158

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

DRUG BANK

DB09310

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

DRUG CENTRAL

5134

Created by admin on Mon Mar 31 20:56:15 GMT 2025 , Edited by admin on Mon Mar 31 20:56:15 GMT 2025

PRIMARY

Glycosylation Type

YEAST

Glycosylation Link Type	Site
N	1_613
N	2_613

Related Record Type Details


					NU23Q531G1

ACTIVE MOIETY

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID SUBSTITION	[1_1] [2_1]		SERINE	Amount:	N-ACETYLSERINE	W98518XGZ3

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER AVERAGE(CALCULATED)	CHEMICAL